Fragile X Syndrome Antibodies

Santa Cruz Biotechnology features a diverse variety of Fragile X Syndrome monoclonal antibodies for advanced research in neurodevelopmental disorders. Fragile X Syndrome Antibodies are compatible with multiple techniques, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). Fragile X Syndrome is caused by a mutation in the FMR1 gene, leading to a deficiency in the fragile X mental retardation protein (FMRP), which plays a crucial role in synaptic function and plasticity. Understanding Fragile X Syndrome is essential for uncovering the underlying mechanisms of cognitive impairment and behavioral issues associated with this condition. Research focused on FMRP can reveal molecular pathways affected by its deficiency and identify potential therapeutic targets. Investigating the role of FMRP in synaptic development provides valuable insights into neuronal communication and plasticity. Examining FMR1 gene expression patterns helps researchers understand the complex regulation of FMRP production. Santa Cruz Biotechnology monoclonal antibodies for Fragile X Syndrome research support scientists worldwide in advancing our understanding of this significant neurodevelopmental disorder.